From environmental impact to implementation pathways: Advancing life‐cycle thinking for transfusion systems in a warming and unequal world

Hibbs and colleagues have taken an important first step in quantifying “What is the environmental impact of a blood transfusion?” by conducting a life-cycle assessment (LCA) of transfusion services across England.1 Their analysis joins a broader movement to measure and mitigate the climate footprint of clinical care, in which transfusion is now evaluated not only for safety and efficacy, but also for its planetary impact.2 The next phase of this agenda, in our view, should move beyond a single national LCA toward implementation-ready frameworks that are (i) pathway-specific, (ii) globally adaptable, and (iii) explicitly linked to health-technology assessment (HTA), guideline development, and service design. First, transfusion LCAs should evolve from average, system-wide estimates to clinical-pathway–specific profiles. Current cross-specialty work shows that carbon emissions vary markedly by specialty and activity, but largely treats blood components as background inputs.2 A natural extension of Hibbs et al.'s model would be to generate emission factors for a small set of high-volume indications (e.g., perioperative care, trauma, obstetric hemorrhage, hematologic malignancies), incorporating context-sensitive parameters such as storage duration, wastage, and emergency versus scheduled use. Linking these emission factors with dynamic databases such as HealthcareLCA would allow regular updating as technologies, energy mixes, and procurement patterns change.2 Second, there is an opportunity to integrate transfusion LCAs into formal HTA processes. McAlister et al. have argued that carbon metrics should stand alongside costs and health outcomes in HTA appraisals.3 In transfusion medicine, this would mean evaluating low-emission options—optimized logistics, point-of-care testing–guided thresholds, or interventions that reduce unnecessary transfusion—using a triple-bottom-line framework of clinical benefit, economic cost, and carbon impact. Such an approach would align LCA work with decisions about patient blood management, minimum stock levels, and cold-chain design. Third, Hibbs et al.'s findings intersect with the emerging literature on “blood deserts” and global transfusion inequity. Kundu and colleagues estimate that 660 million people in eight Indian states live with limited geographic access to banked blood, far below international benchmarks.4 In such settings, innovative delivery models are being explored to close access gaps. Unless their environmental externalities are explicitly measured, however, efforts to expand access could inadvertently create new carbon “hotspots” in low- and middle-income health systems. Finally, drone-enabled blood distribution illustrates both the promise and complexity of “low-carbon” innovation. In Rwanda, unmanned aerial vehicle delivery has shortened emergency delivery times, reduced expiries, and improved stock management.5 Yet the net carbon balance of drone versus road transport remains uncertain once electricity mix, manufacturing, maintenance, and airspace requirements are considered. Embedding LCA from the outset in evaluations of drone-enhanced transfusion networks—particularly in rural districts and disaster-prone regions—would allow health systems to balance speed, reliability, equity, and emissions rather than treating sustainability as a retrospective add-on.4, 5 Taken together, we believe Hibbs et al.1 provide a methodological foundation for a more implementation-oriented question: “Which configurations of transfusion systems can simultaneously maximize access, minimize clinical risk, and reduce carbon emissions across diverse global settings?” To move toward this goal, we suggest that the transfusion community: (i) standardize LCA methods and reporting boundaries for transfusion; (ii) embed carbon metrics into guideline and policy revisions related to patient blood management and emergency preparedness; (iii) co-design new transfusion pathways with communities in low- and middle-income countries, where the tension between access and sustainability is most acute; and (iv) develop an open, transfusion-specific module within existing healthcare LCA platforms to share assumptions and results transparently.2, 3 In summary, Hibbs et al. have shown that blood transfusion has a measurable and non-trivial environmental footprint.1 The next step is to convert this insight into practical, pathway-based implementation strategies that address both global inequities in blood access and the urgent need to decarbonize health care. Doing so would align transfusion medicine with its core ethical commitments: to save lives, to do no harm—including environmental harm—and to ensure that the benefits of innovation reach patients in all regions of the world. The author has disclosed no conflicts of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.